美皓醫療集團有限 公司 M EIH AO M E DIC AL G R O UP C O., LT D 美 皓 醫 療 集 團 有 限公司 MEIHAO MEDICAL GROUP CO., LTD (Incorporated in the Cayman Islands with limited liability) Stock Code: 1947 INTERIM REPORT 2024 中期報告 （於開曼群島註冊成立的有限公司） 股份代號 : 1947 中期報告 2024 2024 INTERIM REPORT and . tes and of the state of the many of the state of the states of the states of the states of the states of the states of the states of the states of the states of the state o 目錄 | --- | --- | |-------|--------------------------| | | | | 2 | 公司資料 | ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 33,797, a decrease of 3.4% from RMB 34,985 for the same period in 2023[3] - Gross profit for the same period was RMB 12,348, down 20.5% from RMB 15,468 in 2023[3] - The company reported a loss before tax of RMB 14,432, compared to a loss of RMB 2,751 in the previous year, indicating a significant increase in losses[3] - Total comprehensive loss for the period was RMB 14,466, compared to a comprehensive income of RMB 1,005 in the same period last year[4] - The company reported a basic and diluted loss per share of RMB 2.51, compared to RMB 0.35 in the previous year, indicating a worsening financial performance[3] - The company reported a basic loss per share attributable to ordinary equity holders of RMB 15,074 thousand for the six months ended June 30, 2024, compared to RMB 2,122 thousand for the same period in 2023, indicating a significant increase in losses[20] - Revenue decreased from RMB 35.0 million for the six months ended June 30, 2023, to RMB 33.8 million for the six months ended June 30, 2024, representing a decline of approximately 3.4%[23] Assets and Liabilities - Non-current assets decreased to RMB 78,172 as of June 30, 2024, from RMB 80,117 as of December 31, 2023[5] - Current assets totaled RMB 146,254, a slight decrease from RMB 152,310 at the end of 2023[5] - The company's cash and cash equivalents increased to RMB 100,462 from RMB 86,827 at the end of 2023, reflecting improved liquidity[5] - Total liabilities increased to RMB 44,255 from RMB 37,959, indicating a rise in financial obligations[5] - The equity attributable to the owners of the parent decreased to RMB 151,504 from RMB 165,178, reflecting a decline in shareholder value[7] - Trade receivables at the end of the reporting period totaled RMB 1,317,789 thousand, a decrease from RMB 1,301,759 thousand as of December 31, 2023[21] - Trade payables at the end of the reporting period amounted to RMB 7,360,000 thousand, up from RMB 6,640,000 thousand as of December 31, 2023, reflecting an increase of approximately 10.9%[22] Revenue Breakdown - Customer contract revenue for the six months ended June 30, 2024, was RMB 33,797 thousand, a decrease of 3.4% from RMB 34,985 thousand in the same period of 2023[12] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 14.3 million, a decrease of about 4.7% year-on-year, accounting for approximately 42.2% of total revenue[36] - Revenue from the Orthodontics Department was approximately RMB 5.7 million, a decrease of about 6.6% year-on-year, representing about 17.0% of total revenue[37] - Revenue from the Oral Restoration Department was approximately RMB 7.1 million, a decrease of 1.4%, accounting for about 21.0% of total revenue[38] - Revenue from the Implant Department increased to approximately RMB 4.3 million, an increase of RMB 0.4 million or 10.3% year-on-year[39] Operational Changes - The total number of active patients decreased from 30,366 to 29,259, a reduction of 3.6% over the same period[27] - The number of active patients at Wenzhou Hospital decreased from 18,908 to 14,545, a decline of approximately 23.2%[27] - The company operates six private dental hospitals and clinics in Wenzhou, Zhejiang Province, focusing on comprehensive dental services across four main areas[23] - The company has increased advertising expenses to attract more customers in response to the impact of the implant dental collection policy on profit margins[23] - The company has implemented a talent acquisition strategy to ensure sustainable development and maintain existing human resources[23] - The implementation of the dental implant collection policy in China has led to a decrease in the number of visits and average spending per visit, posing long-term challenges for dental service providers[29] Future Strategies - The company is optimistic about its future development prospects despite the current challenges[23] - The company plans to increase investment in marketing efforts to capture market opportunities and strengthen its market position[29] - The company aims to expand its service offerings by establishing specialized pediatric dental hospitals to meet rising demand in Wenzhou[30] - Strategic acquisitions are being sought in Zhejiang Province and neighboring provinces to enhance market presence[30] - The company is focusing on upstream investments in medical device companies to stabilize supply chains and reduce procurement costs[31] - Upgrading the business operation software system will improve data integration and management across six dental hospitals and clinics, enhancing service efficiency[33] - Increased advertising investment is expected to improve business capabilities and customer engagement[33] Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and has adopted all applicable corporate governance codes, except for a specific provision regarding the separation of the roles of chairman and CEO[60][61] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the six months ending June 30, 2024, ensuring compliance with accounting policies and disclosure requirements[64] - The interim report for the six months ending June 30, 2024, will be sent to shareholders and published on the company's website[65] - The company expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[66] Employee and Operational Metrics - The company has 323 employees as of June 30, 2024, an increase from 286 employees as of December 31, 2023[53] - Employee benefits expenses for the reporting period amounted to approximately RMB 19.1 million, a decrease of about RMB 1.1 million compared to RMB 20.2 million in the same period of 2023[54] Shareholder Information - The company declared a final dividend of HKD 0.01 per ordinary share, with approximately HKD 5.9 million (approximately RMB 5.4 million) to be paid in cash[19] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2024, consistent with the previous period[59] - The company completed a global offering of 150,000,000 shares at an issue price of HKD 0.84 per share, which is expected to support future business development and expansion in China[48] - The company issued 154,350 shares of bonus shares on June 26, 2024, which began trading on the Hong Kong Stock Exchange on August 15, 2024[56] - The company implemented a share reward plan on January 16, 2024, purchasing a total of 230,000 shares from January 24 to January 25, 2024, representing approximately 0.038% of the total issued shares[57] - The company completed the acquisition of 98.5% of the shares of a private dental service provider, Le Qing Dental Hospital Limited, on December 19, 2023[58] Risk Management - The company is closely monitoring foreign exchange risks, particularly the impact of RMB and HKD exchange rate fluctuations on its financial position[50] - The company has no significant contingent liabilities or guarantees as of June 30, 2024, consistent with the previous year[52] - There were no significant investments or acquisitions during the reporting period[55]

Financial Performance - The company's revenue decreased from RMB 1,274 million to RMB 735 million, representing a decline of approximately 42.3%[9]. - The net loss for the year was approximately RMB 136 million, compared to a net profit of RMB 286 million in the previous year[16]. - Cash and cash equivalents as of December 31, 2023, were RMB 868 million, a decrease of about 3.0% from the previous year[9]. - The net asset value decreased from RMB 1,778 million in 2022 to RMB 1,655 million in 2023[9]. - Gross profit decreased by approximately 58.2% to about RMB 327 million, with a gross margin of approximately 44.4%[40]. - Other income and gains decreased by approximately 40.4% to about RMB 59 million, primarily due to a reduction in government subsidies[41]. - Selling expenses increased by approximately 13.7% to about RMB 207 million, mainly due to an increase in sales and marketing personnel[42]. - Administrative expenses decreased by approximately 15.2% to about RMB 229 million, influenced by the absence of listing expenses from the previous year[43]. - The company recorded a loss attributable to owners of approximately RMB 136 million, compared to a profit of RMB 285 million in the previous fiscal year[45]. Patient Activity and Services - The number of active patients at dental hospitals decreased from 63,659 to 50,324[9]. - The total number of active patients in the five private dental hospitals decreased from 63,659 as of December 31, 2022, to 50,324 as of December 31, 2023, representing a decline of approximately 20.9%[23]. - Total revenue from the five private dental hospitals was RMB 73,513,000 for the year ended December 31, 2023, down from RMB 127,408,000 for the year ended December 31, 2022[24]. - Wenzhou Hospital contributed the largest share of revenue, accounting for approximately 62.4% of total revenue in 2023, with revenue of RMB 45,820,000[25]. - The implementation of the dental implant collection policy in China has led to a decrease in the number of visits and average spending per visit in the implant department, negatively impacting short-term performance[26]. Strategic Initiatives and Growth Plans - The company aims to enhance its market position in China despite challenges from centralized procurement policies affecting implant prices[9]. - The company plans to adopt prudent financial management and cost control measures to drive business growth in the coming year[10]. - The company plans to expand its presence in Wenzhou by establishing more private dental hospitals and seeking strategic acquisitions in Zhejiang Province and neighboring provinces[27]. - The company aims to invest in upstream dental equipment and materials to ensure stable supply and reduce procurement costs, enhancing profit margins[28]. - The focus on children's dental services is expected to drive growth in the dental service market, as the demand from pediatric patients is anticipated to increase[27]. - The company is exploring investments in the medical aesthetics industry to broaden its business scope and increase revenue sources[28]. - The overall strategy includes enhancing brand building and customer satisfaction through comprehensive service offerings and multi-faceted investment directions[28]. Corporate Governance and Management - The board consists of five members, including two executive directors and three independent non-executive directors[98]. - The company has adopted a corporate governance code and believes it has complied with it during the reporting period, except for a specific deviation[90]. - The board of directors is responsible for overall leadership and strategic decision-making, with specific duties including the formulation of annual financial budgets and profit distribution plans[101]. - Independent non-executive directors play a crucial role in supervising the board and providing independent judgment, particularly in cases of potential conflicts of interest[102]. - The board has established three committees: the audit committee, remuneration committee, and nomination committee, each with defined terms of reference[122]. Environmental, Social, and Governance (ESG) Strategies - The report covers the fiscal year ending December 31, 2023, focusing on the group's environmental, social, and governance (ESG) strategies and performance[166]. - The group emphasizes the importance of balancing profitability with environmental and social impacts, aiming for sustainable development and corporate social responsibility[165]. - The board of directors is responsible for ensuring effective implementation of the ESG policies, with dedicated teams managing ESG matters across business segments[164]. - The group has conducted a comprehensive review of existing policies and practices to improve future performance in ESG areas[165]. - Key performance indicators (KPIs) are calculated based on international standards and emission factors as per the guidelines from the Hong Kong Stock Exchange[166]. Waste and Emissions Management - The total greenhouse gas emissions generated during the reporting period amounted to 1,164.3 tons of CO2 equivalent[191]. - The company aims to reduce or maintain the total greenhouse gas emissions density at 90% to 120% of the baseline year (2023) by the end of 2026[191]. - Water consumption during the reporting period was 9,988 cubic meters, with a water consumption density of 34.92 cubic meters per employee[193]. - The total hazardous waste generated was 18,580 kilograms, with a hazardous waste density of 64.97 kilograms per employee[196]. - The company has implemented measures to reduce greenhouse gas emissions, including water management and energy efficiency training for employees[192].

Financial Performance - Revenue decreased by approximately 42.3% to about RMB 73.5 million, compared to RMB 127.4 million for the year ended December 31, 2022[2]. - The company reported a loss before tax of approximately RMB 7.2 million, a decline from a profit of approximately RMB 40.2 million for the year ended December 31, 2022[2]. - Loss attributable to equity holders of the company was approximately RMB 13.6 million, compared to a profit of approximately RMB 28.5 million for the year ended December 31, 2022[2]. - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 2.27, down from earnings of approximately RMB 6.22 for the year ended December 31, 2022[5]. - The group reported a pre-tax loss of RMB 10,478 thousand for 2023, compared to a loss of RMB 15,204 thousand in 2022, indicating a reduction in losses[25]. - The company's gross profit decreased by approximately 58.2% to about RMB 32.7 million, with a gross profit margin dropping to approximately 44.4% from 61.4% in the previous year[71]. - Other income totaled RMB 5,859 thousand in 2023, down from RMB 9,895 thousand in 2022, primarily due to a significant reduction in government grants[24]. - Income tax expenses for the reporting period were approximately RMB 6.4 million, down from RMB 11.6 million for the year ending December 31, 2022, primarily due to a decline in group revenue and losses from several subsidiaries[76]. Assets and Liabilities - Total non-current assets increased to RMB 80,117,000 from RMB 76,211,000, representing a growth of 3.8% year-over-year[7]. - Current assets decreased to RMB 152,310,000 from RMB 176,507,000, a decline of 13.7% year-over-year[7]. - Total liabilities decreased from RMB 74,967,000 in 2022 to RMB 66,882,000 in 2023, a reduction of 10.7%[7]. - Net assets decreased to RMB 165,545,000 from RMB 177,751,000, reflecting a decline of 6.8% year-over-year[8]. - Cash and cash equivalents decreased to RMB 86,827,000 from RMB 89,529,000, a decrease of 3.1%[7]. - The company's equity attributable to owners remained stable at RMB 165,178,000 compared to RMB 177,372,000 in the previous year[8]. - Current assets decreased from approximately RMB 84.0 million as of December 31, 2022, to approximately RMB 7.0 million as of December 31, 2023, mainly due to the collection of RMB 67.1 million from the global offering[78]. - As of December 31, 2023, the group's current assets net value was approximately RMB 114.4 million, with a current ratio of 4.0 times, down from 4.3 times in the previous year[79]. Revenue Breakdown - Revenue from customer contracts for 2023 was RMB 73,513 thousand, a decrease of 42.4% from RMB 127,408 thousand in 2022[21]. - Revenue from the oral comprehensive treatment department was approximately RMB 31.2 million, a decrease of about 2.5% year-on-year, accounting for approximately 42.5% of total revenue during the reporting period[65]. - Revenue from the orthodontics department was approximately RMB 14.4 million, a decrease of about 27.6% year-on-year, representing about 19.7% of total revenue[66]. - Revenue from the oral restoration department was approximately RMB 14.9 million, a decrease of RMB 13.2 million or 47.0%, accounting for about 20.2% of total revenue[67]. - Revenue from the implant dentistry department was approximately RMB 8.0 million, a significant decrease of RMB 34.2 million or 81.0% due to the implementation of centralized procurement policies[68]. Operational Insights - The company operates primarily in the dental services sector, with all external revenue generated from customers in mainland China[17]. - The company operates five private dental hospitals in Wenzhou, Zhejiang Province, focusing on comprehensive dental services[40]. - The total number of active patients in the five private dental hospitals decreased from 63,659 as of December 31, 2022, to 50,324 as of December 31, 2023, representing a decline of approximately 20.9%[50]. - Wenzhou Hospital contributed the largest share of revenue, accounting for approximately 62.4% of total revenue in 2023, with revenue of RMB 45,820,000[53]. - The implementation of the dental implant procurement policy in China has led to a decrease in the number of dental visits and average spending per visit, negatively impacting the group's dental implant services in the short term[54]. - The company plans to continue expanding its market presence by establishing more private dental hospitals in Wenzhou and seeking potential strategic acquisitions in Zhejiang Province or neighboring provinces[57]. - The group aims to penetrate the pediatric dental market further, believing that demand from child patients will drive growth in the dental service market[57]. - The company is enhancing its operational software systems to improve data integration and management across its five dental hospitals, which will increase service efficiency and reduce operational costs[59]. - The group is focused on providing high-quality dental services to build a good reputation and gain customer trust, which is crucial for competitive advantage[59]. Strategic Initiatives - The board has proposed a final dividend of HKD 0.01 per ordinary share, compared to no dividend for the year ended December 31, 2022[2]. - The company intends to invest in upstream and downstream industry chain extensions to stabilize supply sources and reduce procurement costs, thereby enhancing overall competitiveness[58]. - The establishment of a dental training center is planned to cultivate in-house dental talent and improve service professionalism[62]. - The company is focusing on enhancing service quality and customer satisfaction to gain more customer trust and support, aiming for sustainable development[61]. - The group plans to use net proceeds from global offerings for business expansion and working capital, with no major investment plans set as of December 31, 2023[90]. Governance and Compliance - The company has adhered to all applicable corporate governance codes as of December 31, 2023, except for one specific provision[100]. - The audit committee consists of three independent non-executive directors, with Mr. Huang Xihua as the chairman[106]. - The annual report for the year ending December 31, 2023, will be sent to shareholders and published on the company's website at an appropriate time[107]. - The board expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[108].

智通财经APP讯，美皓集团(01947)发布公告，李忠成因其他工作安排已辞任公司公司秘书、公司根据香港联合交易所有限公司证券上市规则第3.05条的授权代表及根据上市规则第19.05(2)条及公司条例(香港法例第622章)第16部在香港代公司接受法律程序文件及通知的代理人，自2024年3月31日起生效。 李先生辞任后，董事会欣然宣布，陈玉颖已获委任为公司的公司秘书、授权代表及法律程序代理人，自2024年3月31日起生效。 ...

Revenue Performance - The total revenue for the six months ended June 30, 2023, decreased to RMB 350 million from RMB 572 million for the same period in 2022, representing a decline of approximately 38.8%[7] - The company's revenue for the reporting period was approximately RMB 35.0 million, a decrease of about 38.8% compared to the same period in 2022[21] - The company reported revenue of RMB 34,985,000 for the six months ended June 30, 2023, a decrease of 38.5% compared to RMB 57,190,000 for the same period in 2022[100] - Customer contract revenue for the six months ended June 30, 2023, was RMB 34,985,000, a decrease of 38.8% compared to RMB 57,190,000 for the same period in 2022[124] Patient Activity - The total number of active patients across the five private dental hospitals decreased from 39,680 to 30,366, a reduction of about 23.5%[13] - The number of active patients at Wenzhou Hospital dropped from 23,811 to 18,908, reflecting a decrease of about 20.5%[13] - The average number of visits for dental services decreased from 29,700 to 23,700, leading to a revenue drop in the oral comprehensive treatment department by approximately 8.5%[22] - Revenue from the orthodontics department decreased by approximately 30.7%, with visits dropping from 5,200 to 3,500[23] - The company noted a gradual increase in patient visits as the impact of COVID-19 diminishes[7] - The company’s subsidiary, Wenzhou Dental Hospital, has reported a 25% increase in patient visits, contributing significantly to overall revenue growth[146] Hospital Revenue Contributions - Revenue contributions from the Wenzhou Hospital accounted for approximately 65.1% of total revenue for the six months ended June 30, 2023, generating RMB 22.76 million[14] - The revenue from the Lucheng Hospital decreased from RMB 13.04 million to RMB 5.05 million, a decline of approximately 61.1%[14] - The revenue from the Wenzhou Oral Hospital decreased from RMB 7.53 million to RMB 3.67 million, a decline of approximately 51.2%[14] - The total revenue from the Longgang Hospital was RMB 2.11 million, contributing 6.0% to total revenue, down from 4.8% in the previous year[14] Financial Performance - Gross profit decreased by approximately 52.6% to about RMB 15.5 million, with the gross margin dropping to approximately 44.2%[28] - The group recorded a loss attributable to the owners of the company of approximately RMB 2.1 million during the reporting period, compared to a profit of RMB 10.9 million for the six months ended June 30, 2022[33] - The company incurred a loss before tax of RMB 2,751,000, compared to a profit of RMB 15,423,000 in the prior year[100] - The net loss attributable to equity holders of the parent was RMB 2,122,000, a significant decline from a profit of RMB 10,863,000 in the same period last year[100] - The company reported a total comprehensive income of RMB 1,005,000 for the six months ended June 30, 2023, compared to RMB 10,873,000 in the previous year[102] Expenses and Cost Management - Selling expenses rose by approximately 63.3% to RMB 9.8 million, attributed to an increase in sales and marketing personnel[30] - Administrative expenses decreased by approximately 9.0% to RMB 10.1 million, influenced by the absence of listing expenses incurred in the previous year[31] - Employee benefit expenses for the reporting period amounted to approximately RMB 20.2 million, an increase of approximately RMB 1.2 million compared to RMB 19.0 million in the same period of 2022[41] - The cost of inventory, consumables, and customized products for the six months ended June 30, 2023, was RMB 5,066,000, down from RMB 6,892,000 in 2022, indicating a reduction of 26.5%[126] Future Outlook and Expansion Plans - The company expressed confidence in future growth due to the gradual recovery from COVID-19 and government support policies[7] - The company plans to expand its dental services in Wenzhou and establish new private dental hospitals to capture rising demand[17] - The company aims to enhance its operational efficiency by upgrading its business operation software systems across its dental hospitals[18] - The company plans to allocate approximately 28.6% of its net proceeds (RMB 21.5 million) for potential strategic acquisitions of two dental hospitals in China by June 2024[95] - The company is planning to expand its market presence by opening two new clinics in Zhejiang province by the end of 2023[146] Capital and Assets - As of June 30, 2023, the group's current assets net value was approximately RMB 135.4 million, with a current ratio of 4.5 times[36] - The group had no bank loans as of June 30, 2023, maintaining a debt-free status[36] - The group had a bank balance of approximately RMB 147.5 million as of June 30, 2023, up from RMB 89.5 million as of December 31, 2022[36] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 208,434,000, a decrease of 1.3% from RMB 211,490,000 as of December 31, 2022[107] - Non-current assets totaled RMB 73,071,000 as of June 30, 2023, down from RMB 76,211,000 at the end of 2022, reflecting a decline of 4.1%[105] Shareholder and Corporate Governance - As of June 30, 2023, the company had a total of 600,000,000 shares issued, with major shareholders JTC BVI and Ricon BVI holding 337,500,000 shares (56.25%) and 45,000,000 shares (7.5%) respectively[56] - The company adopted a share option scheme on November 8, 2022, with a maximum issuance limit of 60,000,000 shares, equivalent to 10% of the total shares issued as of the report date[61] - The company’s directors and senior management hold a combined interest of 71.25% in the company through controlled corporations[55] - The group did not recommend the payment of an interim dividend for the six months ended June 30, 2023, consistent with the previous year[129] Regulatory and Compliance Issues - The company faces risks related to the contractual arrangements, including potential regulatory changes and conflicts of interest with shareholders of the variable interest entity[87] - The company must adhere to specific regulations regarding foreign investment in medical institutions, with local partners required to hold at least 30% equity[85] - The company has received exemptions from the Stock Exchange regarding certain ongoing connected transactions under the contractual arrangements[89] - The group confirmed no significant changes in contractual arrangements with variable interest entities in the six months ending June 30, 2023[81]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二三年六月三十日止六個月的中期業績公告 財務摘要 截至六月三十日止六個月 二零二三年 二零二二年 六月三十日 六月三十日 （人民幣千元）（人民幣千元） （未經審核） （未經審核） 收益 34,985 57,190 銷售成本 (19,517) (24,456) 毛利 15,468 32,734 除稅前（虧損）╱溢利 (2,751) 15,423 期間（虧損）╱溢利 (2,120) 10,873 期間經調整（虧損）╱溢利 (2,120) 14,408 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 茲提述美皓醫療集團有限公司（「本公司」）日期為二零二三年三月二十九日的公告（「該公 告」），內容有關本公司及其附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年 度的經審核綜合財務業績，及本公司截至二零二二年十二月三十一日止年度的年度報告 （「年報」）。除另有界定者外，本公告所用詞彙與該公告及年報所界定者具有相同涵義。 除該公告及年報所披露的資料外，本公司謹此向其股東及本公司潛在投資者就年報第12頁 所披露本公司於二零二二年十二月三十一日的預付款項、其他應收款項及其他資產提供以 下補充資料： 應收包銷商首次公開發售款項（「應收首次公開發售款項」）約人民幣67.1百萬元包含在本公 司 ...

Financial Performance - The company reported a revenue increase from RMB 1.053 billion to RMB 1.274 billion, representing a growth of approximately 21.0%[10]. - The company recorded revenue of approximately RMB 127.4 million for the year ended December 31, 2022, an increase from RMB 105.3 million in 2021, representing a growth of about 21.0%[20]. - The net profit for the year ended December 31, 2022, was approximately RMB 28.6 million, a decrease of about 11.2% compared to RMB 32.2 million in 2021, primarily due to increased listing expenses[20]. - The group's gross profit increased by approximately 16.9% to RMB 78.2 million, with a slight decrease in gross margin to about 61.4%[41]. - Other income and gains rose by approximately 482.4% to RMB 9.9 million, primarily due to increased government subsidies related to the listing[42]. - Selling expenses increased by approximately 256.9% to RMB 18.2 million, mainly due to heightened marketing and promotional expenditures[43]. - Administrative expenses rose to approximately RMB 27.0 million, an increase of about RMB 9.5 million, largely due to increased listing expenses[44]. Patient and Service Growth - The number of active patients at dental hospitals increased from 61,910 to 63,659 during the year[10]. - The total number of active patients increased from 61,910 in 2021 to 63,659 in 2022, reflecting a growth of 2.83%[26]. - The Wenzhou Hospital contributed approximately 60.1% of total revenue in 2022, generating RMB 76.5 million, compared to 70.2% in 2021[27][28]. - The company plans to expand its dental services in Wenzhou by establishing new private dental hospitals to capture rising demand and enhance market presence[30]. - The company aims to penetrate the pediatric dental market, believing that demand from child patients will be a major growth driver in the dental services market[30]. Financial Position and Assets - Cash and cash equivalents rose by approximately 116.7%, reaching RMB 895 million by the end of 2022[10]. - The company's net asset value significantly increased from RMB 505 million in 2021 to RMB 1.778 billion in 2022[10]. - As of December 31, 2022, the group's current assets net amount was approximately RMB 135.3 million, with a current ratio of 4.3 times[48]. - The group had a capital commitment of approximately RMB 2.1 million for leasing property renovations and medical equipment as of December 31, 2022, compared to RMB 0.5 million in 2021[51]. Management and Governance - The management team includes co-founders with nearly 18 years of experience in the dental service industry[59][63]. - The management team includes professionals with extensive backgrounds in finance, healthcare, and technology, ensuring a diverse skill set[70][71]. - The board consists of five members, including two executive directors and three independent non-executive directors, ensuring a balanced mix of skills and experiences[105]. - The company has adopted a board diversity policy that includes criteria such as gender, age, cultural background, and professional qualifications[105]. - The company provides ongoing professional development for directors to keep them updated on regulatory changes and responsibilities[101]. Risk Management and Compliance - The company has implemented multiple systems to identify potential risks related to its business, including quality control systems and emergency response protocols[131]. - The board acknowledges its responsibility for the effectiveness of the risk management and internal control systems[133]. - The company has a zero-tolerance policy towards bribery and corruption, with established reporting mechanisms for corruption allegations[134]. - The audit committee is responsible for overseeing the internal control procedures and ensuring compliance with regulatory requirements[131]. - The company has not established an internal audit function, considering the scale and complexity of its operations[131]. Market and Economic Environment - The overall economic environment in China showed challenges, with GDP growth at only 1% in the second quarter of 2022[9]. - The average disposable income of Wenzhou residents grew by 5.8% year-on-year, reaching RMB 63,033[9]. - The company anticipates a recovery in consumer and retail markets in 2023 as COVID-19 restrictions ease, presenting opportunities for growth[29]. Strategic Plans and Future Outlook - The company aims to strengthen its market position in China following its successful listing on the Hong Kong Stock Exchange on December 14, 2022[8]. - The company plans to implement prudent financial management and cost control to explore suitable business opportunities for growth[10]. - The company is exploring expansion plans into new regions, which carry uncertainties and risks[165]. - New dental clinics will be established outside Wenzhou under a new brand name[91]. - The company will purchase new dental equipment and supplies to enhance service quality[91]. Shareholder Relations and Communication - The company acknowledges the importance of effective communication with shareholders to enhance investor relations and understanding of its business and strategies[147]. - The board of directors is committed to ensuring that all resolutions presented at the annual general meeting are voted on according to listing rules, with results published post-meeting[148]. Contractual Arrangements and Legal Compliance - The exclusive purchase agreement was established on January 16, 2020, and August 26, 2021, ensuring compliance with legal regulations and protecting asset value[184]. - The shareholders' rights entrustment agreement grants 德鴻醫療 control over 100% of 天睿醫療 and other subsidiaries, ensuring decision-making authority[188]. - The company has not faced any intervention or obstruction from Chinese regulatory authorities regarding its contractual arrangements as of December 31, 2022[195]. - The contractual arrangements are specifically designed to address foreign ownership restrictions and align with the company's business objectives while minimizing legal conflicts in China[197].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二二年十二月三十一日止年度的年度業績公告 財務摘要 . 收益增加約21.0%至約人民幣127.4百萬元（二零二一財年：約人民幣105.3百萬元） . 除稅前溢利減少約8.0%至約人民幣40.2百萬元（二零二一財年：約人民幣43.7百萬元） . 本公司權益持有人應佔溢利減少約11.2%至約人民幣28.5百萬元（二零二一財年：約 人民幣32.1百萬元） . 經調整溢利淨額（不包括上市開支）增加約10.8%至約人民幣38.1百萬元（二零二一財 年：約人民幣34.4百萬元） . 母公司普通權益持有人應佔每股盈利減少約12.8%至約人民幣6.22分（二零二一財 年：約人民幣7.13分） ...